CD19-targeted chimeric antigen receptor-modifed T-cell (CAR-T cell) immunotherapy has shown excellent anti-tumor activity in patients with relapsed/refractory acute lympho blastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), which led to the approval of tisagenlecleu cel and axicabtagene ciloleucel by the USA Food and Drug Administration (FDA). A third product was recently approved by FDA: lisocabtagene maraleucel for R/R NHL. CAR-T cells can be associated with unique early toxicities, such as cytokine release syndrome (CRS) [4] and immune efec tor cell associated acute neurotoxicity syndrome (ICANS). Potential long-term events after this novel therapy are still unknown. Here, we describe a case of myelodysplastic syndrome (MDS) arising 21 months after the procedure as potential long-term consequence of this new strategy. A 53-year-old woman received in April 2009 a diagnosi
Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity? / Di Rocco, A.; Di Palma, M.; D'Elia, G. M.; Iaquinta, G.; Breccia, M.; Mancini, F.; Grammatico, P.; Martelli, M.. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - (2023). [10.1007/s00277-023-05329-9]
Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity?
Di Rocco A.;Iaquinta G.;Breccia M.;Grammatico P.;Martelli M.
2023
Abstract
CD19-targeted chimeric antigen receptor-modifed T-cell (CAR-T cell) immunotherapy has shown excellent anti-tumor activity in patients with relapsed/refractory acute lympho blastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), which led to the approval of tisagenlecleu cel and axicabtagene ciloleucel by the USA Food and Drug Administration (FDA). A third product was recently approved by FDA: lisocabtagene maraleucel for R/R NHL. CAR-T cells can be associated with unique early toxicities, such as cytokine release syndrome (CRS) [4] and immune efec tor cell associated acute neurotoxicity syndrome (ICANS). Potential long-term events after this novel therapy are still unknown. Here, we describe a case of myelodysplastic syndrome (MDS) arising 21 months after the procedure as potential long-term consequence of this new strategy. A 53-year-old woman received in April 2009 a diagnosiI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
